• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Viatris

Viatris, Kindeva win FDA approval for first generic version of Symbicort inhalation aerosol

March 16, 2022 By Sean Whooley

Viatris Kindeva Drug Delivery

Viatris (Nasdaq:VTRS) and Kindeva Drug Delivery announced today that the FDA approved its generic version of AstraZeneca’s Symbicort. In March 2021, the FDA granted tentative approval to Breyna (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol) — the first generic version of Symbicort. Today, the agency granted approval for the abbreviated new drug application (ANDA) for […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Respiratory Tagged With: AstraZeneca plc, FDA, Kindeva Drug Delivery, Viatris

Prime Therapeutics to prefer Viatris’ interchangeable insulin biosimilar

November 3, 2021 By Sean Whooley

Viatris Biocon

Pharmacy benefit manager Prime Therapeutics announced today that it will prefer Viatris’ (NSDQ:VTRS) Semglee insulin biosimilar injection on its national formularies as part of the pharmacy benefit. In July, the FDA cleared the Semglee insulin glargine-yfgn injection, developed by Viatris in collaboration with Biocon Biologics, as a biosimilar for controlling high blood sugar in adults […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: biocon, Prime Therapeutics, Viatris

FDA approves insulin glargine biosimilar injection from Viatris, Biocon Biologics

July 29, 2021 By Sean Whooley

Viatris Biocon

Viatris (NSDQ:VTRS) and Biocon Biologics announced FDA clearance for their Semglee insulin glargine-yfgn injection as a biosimilar. Semglee holds an indication for controlling high blood sugar in adults with type 2 diabetes and pediatric patients with type 1 diabetes. The FDA approved Semglee as the first interchangeable biosimilar product under the 351(k) regulatory pathway. The […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA) Tagged With: biocon, Viatris

Pfizer agrees to pay $345M in EpiPen pricing lawsuit

July 16, 2021 By Sean Whooley

legal

Pfizer (NYSE:PFE) agreed to pay $345 million to settle claims of overpayments for EpiPens due to alleged anti-competitive and unfair practices. Reuters reported that a filing disclosed in federal court in Kansas City, Kan., revealed the settlement set to resolve claims from consumers who say they overpaid for EpiPens with the alleged anti-competitive and unfair practices […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Legal News, Pharmaceuticals Tagged With: epipen, Mylan, Pfizer Inc., Viatris

Kansas Distric Court rules in favor of Mylan in EpiPen class action

June 24, 2021 By Sean Whooley

legal

Viatris (NSDQ:VTRS) announced that the U.S. District Court for the District of Kansas ruled in favor of Mylan in an EpiPen class action. Mylan, which Pfizer combined with its Upjohn business to form Viatris in November 2020, received a favorable ruling in substantial part that dismissed all of the plaintiffs’ claims under the federal RICO […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Legal News, Pharmaceuticals Tagged With: epipen, Mylan, Viatris

FDA tentatively approves first generic version of Symbicort inhalation aerosol

March 8, 2021 By Sean Whooley

Viatris Kindeva Drug Delivery

Viatris (NSDQ:VTRS) and Kindeva Drug Delivery announced today that the FDA granted tentative approval of the first generic version of Symbicort. Symbicort, an inhalation aerosol is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD). The drug had U.S. branded sales of $3.5 billion for the 12 months ended January 2021, according […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Legal News, Pharmaceuticals, Regulatory/Compliance, Respiratory Tagged With: AstraZeneca plc, FDA, Kindeva Drug Delivery, Viatris

Mylan must face EpiPen racketeering lawsuit

January 21, 2021 By Nancy Crotti

legal

A federal judge in Minnesota has decided that Mylan must face a lawsuit accusing it of paying bribes and kickbacks to pharmacy benefit managers and of conspiring to fix prices on its EpiPen device. Drug wholesalers Rochester Drug CoOperative and Dakota Drug filed separate but similar lawsuits in March 2020 and June 2020, respectively, claiming […]

Filed Under: Auto-injectors, Business/Financial News, Featured, Legal News Tagged With: epipen, Mylan, Viatris

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS